June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
O’Brien, S.

S868 EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)

Bannerji, R.; Arnason, J.; Advani, R.; More

HemaSphere. 3(S1):388-389, June 2019.

PS949 INOTUZUMAB OZOGAMICIN (INO) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): OUTCOMES OF PATIENTS TREATED IN SALVAGE ONE WITH A LONG DURATION OF FIRST REMISSION

Stelljes, M.; Jabbour, E.; Advani, A.; More

HemaSphere. 3(S1):427-428, June 2019.

PS950 EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED IN THE INO-VATE TRIAL: OUTCOMES BY SALVAGE-TREATMENT PHASE

Jabbour, E.; Stelljes, M.; Advani, A.S.; More

HemaSphere. 3(S1):428, June 2019.

Author:
O’Brien, S.M.

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES

Allan, J.N.; Patel, K.; Mato, A.R.; More

HemaSphere. 3(S1):520, June 2019.

Author:
O’Byrne, S.

PF153 MLL-AF4 CAUSES ABERRANT UPREGULATION OF PROM1 (CD133) IN ACUTE LYMPHOBLASTIC LEUKEMIA BY CONTROLLING ENHANCER-PROMOTER INTERACTIONS

Godfrey, L.; O’Byrne, S.; Crump, N.T.; More

HemaSphere. 3(S1):29, June 2019.

Author:
O’Connell, A.

PF272 GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE

Wang, E.S.; Heuser, M.; Montesinos, P.; More

HemaSphere. 3(S1):87, June 2019.

PF292 LOW-DOSE CYTARABINE WITH OR WITHOUT GLASDEGIB IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

Papayannidis, C.; Smith, B.D.; Heuser, M.; More

HemaSphere. 3(S1):97-98, June 2019.

PS1029 CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL

Heuser, M.; Fiedler, W.; Sekeres, M.A.; More

HemaSphere. 3(S1):464-465, June 2019.

Author:
O’Connor, D.

PS948 EXCELLENT RESPONSE TO BLINATUMOMAB IN REFRACTORY B LINEAGE ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN AND YOUNG ADULTS AFTER DEBULKING CHEMOTHERAPY TO ACHIEVE PARTIAL REMISSION

Clesham, K.; Rao, V.; Bartram, J.; More

HemaSphere. 3(S1):427, June 2019.

Author:
O’Connor, O.

PS1070 THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3(S1):484-485, June 2019.

Author:
O’Dwyer, K.M.

PS945 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3

Shah, B.D.; Bishop, M.R.; Oluwole, O.O.; More

HemaSphere. 3(S1):426, June 2019.

Author:
O’Dwyer, M.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

Author:
O’Hare, T.
Author:
O’Keefe, K.
Author:
O’Mara, E.

PF677 DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

Niemeyer, C.M.; Flotho, C.; Lipka, D.B.; More

HemaSphere. 3(S1):292, June 2019.

Author:
O’Rourke, C.

S854 IMR-687, A HIGHLY SELECTIVE PHOSPHODIESTERASE 9 INHIBITOR (PDE9I), DEMONSTRATES PRELIMINARY EVIDENCE OF ACTIVITY ON RED AND WHITE CELL BIOMARKERS IN A PH-2A INTERIM ANALYSIS

Andemariam, B.; Johnson, K.; Gordeuk, V.; More

HemaSphere. 3(S1):381-382, June 2019.

Author:
O’Rourke, L.

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

Dimopoulos, M.A.; San-Miguel, J.; White, D.; More

HemaSphere. 3(S1):247-248, June 2019.

S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3(S1):364, June 2019.

Author:
Oakervee, H.
Author:
Oakes, C.
Author:
Oakey, R.
Author:
Obara, N.

PS1115 THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3(S1):504-505, June 2019.

PS1308 TARGETING T-CELL RECEPTOR SIGNALING PATHWAY BY DASATINIB IN RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

Kiyoki, Y.; Sakata-Yanagimoto, M.; Nguyen, T.B.; More

HemaSphere. 3(S1):597, June 2019.

Author:
Oberg, H.-H.

S129 TP53 SOMATIC MUTATIONS AS PRE-LEUKEMIC EVENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chitadze, G.; Stengel, A.; John-Klaua, C.; More

HemaSphere. 3(S1):16-17, June 2019.

Author:
Obergan, T.
Author:
Oberic, L.

PF482 CLINICAL EFFICACY OF THE RIBVD REGIMEN FOR REFRACTORY/RELAPSED (R/R) MANTLE CELL LYMPHOMA (MCL) PATIENTS: A RETROSPECTIVE STUDY OF THE LYSA GROUP

Regny, C.; Oberic, L.; guillaume, M.; More

HemaSphere. 3(S1):193, June 2019.

PS1264 FRENCH IBRUTINIB OBSERVATIONAL STUDY (FIRE): REAL-WORLD STUDY OF IBRUTINIB TREATMENT FOR MANTLE CELL LYMPHOMA (MCL) IN FRANCE

Slama, B.; Delmer, A.; Cartron, G.; More

HemaSphere. 3(S1):578-579, June 2019.

Author:
Obermüller, J.
Author:
Obr, A.

PF296 UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS

Duell, J.; Maddocks, K.; González Barca, E.; More

HemaSphere. 3(S1):100, June 2019.

Author:
Obreja, M.
Author:
Obuchova, T.
Author:
Obukhova, T.

PB2016 RESULTS OF TREATMENT PATIENTS OF MANTLE CELL LYMPHOMA DEPENDING ON THE MUTATIONAL STATUS OF THE TP53 GENE

Koroleva, D.; Zvonkov, E.; Gabeeva, N.; More

HemaSphere. 3(S1):912, June 2019.

Author:
Ocak, S.
Author:
Ochi, Y.

PS983 NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3(S1):442, June 2019.

Author:
Ochiai, T.
Author:
Ochirova, O.
Author:
Ochoa, P.

PS1402 OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM

Peña, C.; Schutz, N.P.; Bove, V.; More

HemaSphere. 3(S1):643-644, June 2019.

Author:
Ochrem, B.
Author:
Ocias, L. Frans

PB2210 IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA-2 OR HYDROXYUREA IN THE DALIAH TRIAL

Patel, D.; Knudsen, T. Alma; Hansen, D. Lund; More

HemaSphere. 3(S1):990-991, June 2019.

Author:
Ocio, E.

PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR

Pour, L.; Efebera, Y.A.; Granell, M.; More

HemaSphere. 3(S1):257-258, June 2019.

S871 CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3(S1):390, June 2019.

PB2350 EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA. RETROSPECTIVE ANALYSIS IN OUR CENTER

Romero, Y. Gonzalez; Mora, J.; Cortes, M. A.; More

HemaSphere. 3(S1):1047, June 2019.

Author:
Ocio, E.M.

PF609 HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT

Puig, N.; Contreras, T.; Paiva, B.; More

HemaSphere. 3(S1):258, June 2019.

PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS

Puig, N.; Paíno, T.; Pérez, J.J.; More

HemaSphere. 3(S1):617-618, June 2019.

PS1398 RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT

Dávila, J.; González-Calle, V.; Puig, N.; More

HemaSphere. 3(S1):641-642, June 2019.

Author:
Oda, T.

PF184 EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3(S1):44, June 2019.

Author:
Odame, I.

S839 PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)

Navada, S.C.; Garcia-Manero, G.; Atallah, E.; More

HemaSphere. 3(S1):373-374, June 2019.

Author:
Oddolo, D.

PF579 TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA

Muccio, V.E.; Gilestro, M.; Saraci, E.; More

HemaSphere. 3(S1):241-242, June 2019.

Author:
Odenike, O.

PF254 RESULTS FROM THE FIRST-IN-HUMAN STUDY OF MIVEBRESIB (ABBV-075), A PAN-INHIBITOR OF BROMODOMAIN AND EXTRA TERMINAL PROTEINS, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Borthakur, G.; Odenike, O.; Wolff, J.E.; More

HemaSphere. 3(S1):78, June 2019.

Author:
Odero, M.D.
Author:
Odievre, M.-H.
Author:
Odilov, A.
Author:
Odinius, T.

PS1327 PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML

Dill, V.; Jilg, S.; Wagner, C.; More

HemaSphere. 3(S1):605-606, June 2019.

Author:
Odom, D.

PF626 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3

Schjesvold, F.; Goldschmidt, H.; Maisnar, V.; More

HemaSphere. 3(S1):266-267, June 2019.

Author:
Oehler, V.G.

PF253 SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS

Howard, N.P.; Halpern, A.B.; Othus, M.; More

HemaSphere. 3(S1):78, June 2019.

S877 SAFETY AND CLINICAL ACTIVITY OF AMV564, A CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 1 FIRST-IN-HUMAN TRIAL

Westervelt, P.; Roboz, G.J.; Cortes, J.E.; More

HemaSphere. 3(S1):393-394, June 2019.

Author:
Oerlemans, S.
Author:
Oers, M.H. van

PS1141 PROTEOMICS MARKERS PROGNOSTIC FOR OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER TREATMENT; RESULTS FROM THE HOVON-109 STUDY

Hosnijeh, F. Saberi; Kater, A.P.; Oers, M.H. van; More

HemaSphere. 3(S1):517, June 2019.

Author:
Oevermann, L.
Author:
Offidani, M.

PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3(S1):254-255, June 2019.

S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS

Gay, F.; Cerrato, C.; Rota Scalabrini, D.; More

HemaSphere. 3(S1):390-391, June 2019.

Author:
Offner, F.

S107 FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Tedeschi, A.; Burger, J.; Barr, P.M.; More

HemaSphere. 3(S1):5-6, June 2019.

PF483 EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY

Leonard, J.P.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3(S1):193-194, June 2019.

PS1157 EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Ghia, P.; Flinn, I.; Lamanna, N.; More

HemaSphere. 3(S1):525, June 2019.

PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

Gribben, J.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3(S1):571-572, June 2019.

PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

Thieblemont, C.; Leonard, J.P.; Trneny, M.; More

HemaSphere. 3(S1):577-578, June 2019.

Author:
Ofiteru, G.

PB1760 CHARACTERISTICS OF DIAGNOSIS AND TREATMENT OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 60 YEARS-ANALYSES OF SINGLE CENTER

Popov, V.; Georgescu, D.; Andreescu, M.; More

HemaSphere. 3(S1):808-809, June 2019.

Author:
Ofran, Y.

PF287 MIDOSTAURIN IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IS SAFE AND ASSOCIATED WITH IMPROVED REMISSION AND HIGHER TRANSPLANT RATES IN REMISSION - A MULTI-CENTER HISTORICAL CONTROL STUDY

Berger, T.; Rozovski, U.; Moshe, Y.; More

HemaSphere. 3(S1):95, June 2019.